[144] Immunocore Holdings plc SEC Filing

Immunocore plc reported planned insider stock sales via Form 144.

Rhea-AI Filing Summary

Immunocore plc reported planned insider stock sales via Form 144. The filing lists multiple proposed disposals of American Depositary Receipts (ADRs) by David Berman on dates in November and December 2025, with individual ADR quantities and aggregated dollar values shown for each sale date.

Insights

Securities Compliance Analyst

Form 144 lists multiple insider ADR dispositions by David Berman in late 2025.

The notice records proposed sales of ADRs on specific dates in November and December 2025, each row showing ADR counts and corresponding dollar amounts. This form notifies the market of planned sales under Rule 144.

Timing and execution details beyond the listed dates are not provided in the excerpt; subsequent Form 4 or trade confirmations would show executed transactions and exact proceeds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Immunocore's (IMCR) Form 144 disclose?

The Form 144 discloses proposed insider sales of ADRs by David Berman on specific dates in November and December 2025. The filing lists quantities of ADRs and corresponding dollar amounts for each listed sale date, serving as a public notice under Rule 144.

How many ADR sales are listed in the IMCR Form 144 excerpt?

The excerpt lists multiple sale entries on separate dates in November and December 2025, with ADR counts per date such as 69,404 and smaller lots. Each entry pairs an ADR quantity with a dollar value to show the size of that proposed disposal.

Does the Form 144 confirm the trades were executed for IMCR?

No, Form 144 provides notice of proposed sales; it does not itself confirm execution. Execution and final reporting would appear in subsequent transaction reports, such as Form 4 filings or broker confirmations, which are not included in this excerpt.

Who is the reporting person named on the IMCR Form 144?

The reporting person shown is David Berman, listed with a c/o address at Immunocore LLC in Gaithersburg, MD. The filing attributes the listed ADR sale quantities and dollar amounts to that reporting person on the specified dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001955244
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Immunocore Holdings PLC
SEC File Number	001-39992
Address of Issuer	9801 Washingtonian Boulevard, Suite 800 Gaithersburg MARYLAND 20878
Phone	4845345261
Name of Person for Whose Account the Securities are To Be Sold	David Berman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Ave 10th Floor New York NY 10017	5965	192951.1	50387068	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/17/2026	RSU Vest	Immunocore LLC (issuer)			11824	02/17/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	12/04/2025	31341	1261788.66
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	12/05/2025	572	22960.08
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/26/2025	69404	2784488.48
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/28/2025	5521	221336.89
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/24/2025	100	4000
David Berman c/o Immunocore LLC 9801 Washingtonian Boulevard, Suite 800 Gaithersburg MD 20878	ADRs	11/25/2025	18020	721340.6

144: Remarks and Signature

Remarks
Date of Notice	02/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	J.P. Morgan Securities LLC, Workplace Solutions, as Agent and Attorney in Fact for David Berman, Immunocore Holdings LLC
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)